<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996177</url>
  </required_header>
  <id_info>
    <org_study_id>CR003943</org_study_id>
    <secondary_id>FEN-PPA-401</secondary_id>
    <secondary_id>2004-001201-10</secondary_id>
    <nct_id>NCT00996177</nct_id>
  </id_info>
  <brief_title>A Study to Compare Patient-controlled Pain Medications Delivered Either Through the Skin or Intravenously</brief_title>
  <acronym>EuroTrans</acronym>
  <official_title>Comparison of Transdermal Fentanyl PCA and IV Morphine PCA in the Management of Postoperative Pain Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag International NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alza Corporation, DE, USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen-Cilag International NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of a patient-controlled
      system to deliver fentanyl compared with a patient-controlled intravenous system to deliver
      morphine in the management of postoperative pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (study drug assigned by chance), open-label (all people involved know
      the identity of the intervention) study to evaluate the clinical use, safety and ease of care
      of two patient-controlled analgesia (PCA) systems to deliver pain medication either through
      the skin or intravenously. The fentanyl hydrochloride PCA system, which delivers the
      medication through the skin, and morphine intravenous (IV)- PCA, which requires injection
      into a vein, are used for management of moderate to severe acute pain in postoperative
      patients who have undergone elective major abdominal or orthopedic surgery. These patients,
      who are expected to require postoperative pain relief with strong opioids for at least 24
      hours, will control the delivery of medication for up to 3 days. Assessment of effectiveness
      include: patient's global assessment of pain control (poor, fair, good, excellent); Pain
      Intensity, measured on a visual numerical rating scale from 0 to 10, where 0 means no pain
      and 10 means the worst possible pain; Ease-of-Care questionnaires including Patient
      Ease-of-Care questionnaire, Nurse Ease-of-Care questionnaire, and Physical Therapist
      Ease-of-Care questionnaire; and, total number of doses delivered by patients in the fentanyl
      transdermal PCA or morphine IV PCA treatment groups. Safety evaluations include vital signs
      (pulse, blood pressure) and oxygen saturation, respiratory function, and the incidence of
      adverse events. The study hypothesis is that fentanyl transdermal PCA is not inferior to
      morphine IV PCA treatment in patient's global assessment of method of pain control during the
      first 24 hours after surgery. Transdermal PCA: 40 micrograms fentanyl per on-demand dose,
      each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours (maximum of 80 doses,
      3.2milligrams). Morphine IV PCA: morphine doses with a maximum of 20 milligrams per 2 hours
      for 24 hours (maximum 12 doses, 240 milligrams).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient's global assessment of pain control (poor, fair, good, excellent) 24 hours after start of study treatment</measure>
    <time_frame>24 hours after randomization (24 hours after either the first transdermal iontorphoretic system was applied or 24 hours after the intravenous access for the morphine solution was applied).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pain control by patient and doctor</measure>
    <time_frame>At 24, 48, and 72 hours after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity, vital signs, and oxygen level in the blood</measure>
    <time_frame>Hourly through 8 hours and then every 4 hours after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">657</enrollment>
  <condition>Pain</condition>
  <condition>Analgesia, Patient-Controlled</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>IONSYS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient-Controlled Analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Morphine Patient-Controlled Analgesia (IV PCA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem</intervention_name>
    <description>40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day</description>
    <arm_group_label>IONSYS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Morphine Patient-Controlled Analgesia (IV PCA)</intervention_name>
    <description>20mg/2hr (240 mg during 24 hours)</description>
    <arm_group_label>Patient-Controlled Analgesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet the criteria of American Society of Anesthesiology (ASA)
             pre-operative physical status I, II, or III

          -  Patients expected to have moderate or severe pain after a major abdominal or
             orthopedic procedure

          -  Patients expected to remain hospitalized for at least 24 hours postoperatively

        Exclusion Criteria:

          -  Known allergy or hypersensitivity to fentanyl, morphine, or to skin adhesives

          -  Known or suspected to be dependent on strong opioids or to have abused any drug
             substance or alcohol

          -  Severe respiratory symptoms

          -  Chronic pain disorder

          -  Pregnant or nursing women, or those lacking adequate contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen-Cilag International NV Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen-Cilag International NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kÿbenhavn Nv N/A</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kÿbenhavn Ÿ</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ÿrhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulogne Billancourt Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt / Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg N/A</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kÿln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huddinge N/A</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linköpng N/A</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genève</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zuerich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>N/a N/a</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Grond S, Hall J, Spacek A, Hoppenbrouwers M, Richarz U, Bonnet F. Iontophoretic transdermal system using fentanyl compared with patient-controlled intravenous analgesia using morphine for postoperative pain management. Br J Anaesth. 2007 Jun;98(6):806-15. Erratum in: Br J Anaesth. 2008 Jan;100(1):146.</citation>
    <PMID>17519263</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>January 28, 2014</last_update_submitted>
  <last_update_submitted_qc>January 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Patient-controlled analgesia</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Transdermal fentanyl</keyword>
  <keyword>Surgical pain</keyword>
  <keyword>Opioid analgesics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

